ArticleBreast cancer research and treatment2024

Combination of monensin and erlotinib synergistically inhibited the growth and cancer stem cell properties of triple-negative breast cancer by simultaneously inhibiting EGFR and PI3K signaling pathways.

Tian Fang et al.PubMed ↗Publisher ↗

No numbers read from the abstract.